Stem Cell Infusion in the Treatment of Patients With Neurological Complications After Ischemic Stroke
Ischemic Stroke
About this trial
This is an interventional treatment trial for Ischemic Stroke focused on measuring Ischemic Stroke, umbilical cord mesenchymal stem cells, Neurological Complication
Eligibility Criteria
- Age: from 40 to 75 years.
- Gender: either sex
Patients have been discharged/patients who are hospitalized but their general condition is stable:
- No need for vasopressor drugs
- No need for mechanical ventilation or oxygen support
- No signs of infection (fever, high WBC, high CRP/Procalcitonin)
- No kidney failure, liver failure, heart failure.
- Time from onset to study participation ≤ 24 months
- National Institutes of Health Stroke Scale (NIHSS) score >=5
- Agree to participate in the study
Exclusion Criteria:
- Hematologic cause of stroke
- There is evidence of active infections, failure of heart, lung, liver, or kidney, respiratory distress syndrome, anemia, clotting disorder
- Cancer.
- Pregnancy.
- Tracheostomy, coma, complete quadriplegia, vegetative.
Sites / Locations
- Vinmec Research Institute of Stem Cell and Gene TechnologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Other
UC-MSC infusion via intravenous route
UC-MSC infusion via intrathecal route
control arm
1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
standard stroke treatment and rehabilitation therapy